Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of Minimal Information for Chemosensitivity Assays (MICHA), accessed via https://micha-protocol.org. Distinguished from existing efforts that are often lacking support from data integration tools, MICHA can automatically extract publicly available information to facilitate the assay annotation including: 1) compounds, 2) samples, 3) reagents and 4) data processing methods. For example, MICHA provides an integrative web server and database to obtain compound annotation including chemical structures, targets and disease indications. In addition, the annotation of cell line samples, assay protocols and literature references can be greatly eased by retrieving manually curated catalogues. Once the annotation is complete, MICHA can export a report that conforms to the FAIR principle (Findable, Accessible, Interoperable and Reusable) of drug screening studies. To consolidate the utility of MICHA, we provide FAIRified protocols from five major cancer drug screening studies as well as six recently conducted COVID-19 studies. With the MICHA web server and database, we envisage a wider adoption of a community-driven effort to improve the open access of drug sensitivity assays.

Biotech Research and Innovation Centre University of Copenhagen Denmark

European Infrastructure for Translational Medicine UK

Fraunhofer Institute for Molecular Biology and Applied Ecology Germany

Institute for Molecular Medicine Finland University of Helsinki Finland

Institute of Molecular and Translational Medicine Czech

Istituto di Ricerche Farmacologiche Mario Negri IRCCS Italy

National Center for Advancing Translational Sciences USA

Research Program in Systems Oncology Faculty of medicine University of Helsinki Finland

bioRxiv. 2021 Jun 12:2020.12.03.409409. doi: 10.1101/2020.12.03.409409. PubMed

See more in PubMed

Hatzis C, Bedard PL, Birkbak NJ, et al. . Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res 2014;74:4016–23. PubMed PMC

Haverty PM, Lin E, Tan J, et al. . Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 2016;533:333–7. PubMed

Larsson P, Engqvist H, Biermann J, et al. . Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens. Sci Rep 2020;10:1–12. PubMed PMC

Taylor CF, Field D, Sansone S-A, et al. . Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 2008;26:889–96. PubMed PMC

Orchard S, Al-Lazikani B, Bryant S, et al. . Minimum information about a bioactive entity (MIABE). Nat Rev Drug Discov 2011;10:661–9. PubMed

Abeyruwan S, Vempati UD, Küçük-McGinty H, et al. . Evolving BioAssay ontology (BAO): modularization, integration and applications. J Biomed Semantics 2014;5:1. PubMed PMC

Mendez D, Gaulton A, Bento AP, et al. . ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res 2019;47:D930–40. PubMed PMC

Iorio F, Knijnenburg TA, Vis DJ, et al. . A landscape of pharmacogenomic interactions in cancer. Cell 2016;166:740–54. PubMed PMC

Barretina J, Caponigro G, Stransky N, et al. . The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603. PubMed PMC

Seashore-Ludlow B, Rees MG, Cheah JH, et al. . Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015;5:1210–23. PubMed PMC

Weston S, Coleman CM, Haupt R, et al. . Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J Virol 2020;94:e01218–20. PubMed PMC

Gordon DE, Jang GM, Bouhaddou M, et al. . A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020;583:459–68. PubMed PMC

Touret F, Gilles M, Barral K, et al. . In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep 2020;10:13093. PubMed PMC

Jeon S, Ko M, Lee J, et al. . Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 2020;64:e00819–20. PubMed PMC

Brimacombe KR, Zhao T, Eastman RT, et al. . An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv 2020;2020.06.04:135046.

Ellinger B, Bojkova D, Zaliani A, et al. . A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Sci Data 2021;8:70. PubMed PMC

He L, Kulesskiy E, Saarela J, et al. . Methods for high-throughput drug combination screening and synergy scoring. Cancer Syst Biol 2018;351–98. PubMed PMC

Bolis M, Garattini E, Paroni G, et al. . Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid. Ann Oncol 2017;28:611–21. PubMed PMC

Tanoli Z, Alam Z, Vähä-Koskela M, et al. . Drug target commons 2.0: a community platform for systematic analysis of drug–target interaction profiles. Database 2018;2018:1–13. PubMed PMC

Tang J, Tanoli Z-R, Ravikumar B, et al. . Drug target commons: a community effort to build a consensus Knowledge Base for drug-target interactions. Cell Chem Biol 2018;25:224–9. PubMed PMC

Gilson MK, Liu T, Baitaluk M, et al. . BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res 2016;44:D1045–53. PubMed PMC

Gaulton A, Hersey A, Nowotka M, et al. . The ChEMBL database in 2017. Nucleic Acids Res 2016;45:D945–54. PubMed PMC

Alexander SP, Kelly E, Marrion NV, et al. . The concise guide to pharmacology 2017/18: overview. Br J Pharmacol 2017;174:S1–S16. PubMed PMC

Wagner AH, Coffman AC, Ainscough BJ, et al. . DGIdb 2.0: mining clinically relevant drug–gene interactions. Nucleic Acids Res 2016;44:D1036–44. PubMed PMC

Wishart DS, Knox C, Guo AC, et al. . DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668–72. PubMed PMC

Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech 2018;29:25–38. PubMed PMC

Cichonska A, Pahikkala T, Szedmak S, et al. . Learning with multiple pairwise kernels for drug bioactivity prediction. Bioinformatics 2018;34:i509–18. PubMed PMC

Cichonska A, Ravikumar B, Parri E, et al. . Computational-experimental approach to drug-target interaction mapping: a case study on kinase inhibitors. PLoS Comput Biol 2017;13:e1005678. PubMed PMC

Zeng X, Zhu S, Hou Y, et al. . Network-based prediction of drug–target interactions using an arbitrary-order proximity embedded deep forest. Bioinformatics 2020;36:2805–12. PubMed PMC

Tang J, Gautam P, Gupta A, et al. . Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. NPJ Syst Biol Appl 2019;5:1–11. PubMed PMC

Cheng F, Kovács IA, Barabási AL. Network-based prediction of drug combinations. Nat Commun [Internet]. 2019;10:1197. PubMed PMC

Gross AM, Wolters PL, Dombi E, et al. . Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020;382:1430–42. PubMed PMC

Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64–76. PubMed PMC

Tanoli Z, Seemab U, Scherer A, et al. . Exploration of databases and methods supporting drug repurposing: a comprehensive survey. Brief Bioinform 2021;22:1656–78. PubMed PMC